Schroff R W, Foon K A, Billing R J, Fahey J L
Blood. 1982 Feb;59(2):207-15.
A panel of monoclonal antibodies reactive with normal lymphocyte subsets was used to classify cases of lymphocytic leukemia on the basis of cell surface antigen expression. The antibodies employed were commercially available and included a common framework HLA-DR antibody, two pan-T antibodies (Leu-1 and OKT-3), and antibodies defining cytotoxic/suppressor (Leu-2 and OKT-8) and helper/inducer (Leu-3 and OKT-4) subpopulations of normal T lymphocytes. Cases of ALL could be subgrouped into non-T non-B, pre-T and T-ALL on the basis of reactivity with HLA-DR, Leu-1, and OKT-3 antibodies. Leukemic cells from patients with T-cell CLL could be divided into Leu-2/OKT-8 reactive and Leu-3/OKT-4 reactive subpopulations, as well as a subgroup in which the majority of cells were unreactive with either of these antibodies. With the exception of one individual, all Sézary cell leukemias expressed a phenotypic pattern similar to that of the Leu-3 subgroup of T-CLL. Malignancies of B-cell lineage (B-CLL, prolymphocytic leukemia, and lymphosarcoma) that were examined were reactive with both the HLA-DR and Leu-1 antibodies. On the contrary, normal B lymphocytes and lymphoid cell lines of B-cell origin did not express surface antigens recognized by the Leu-1 antibody.
一组与正常淋巴细胞亚群反应的单克隆抗体被用于根据细胞表面抗原表达对淋巴细胞白血病病例进行分类。所使用的抗体为市售产品,包括一种常见构架的HLA - DR抗体、两种泛T抗体(Leu - 1和OKT - 3),以及定义正常T淋巴细胞细胞毒性/抑制性(Leu - 2和OKT - 8)和辅助/诱导性(Leu - 3和OKT - 4)亚群的抗体。根据与HLA - DR、Leu - 1和OKT - 3抗体的反应性,ALL病例可分为非T非B、前T和T - ALL亚组。T细胞CLL患者的白血病细胞可分为对Leu - 2/OKT - 8有反应和对Leu - 3/OKT - 4有反应的亚群,以及一个大多数细胞对这两种抗体均无反应的亚组。除1例个体外,所有Sezary细胞白血病均表现出与T - CLL的Leu - 3亚组相似的表型模式。所检测的B细胞系恶性肿瘤(B - CLL、原淋巴细胞白血病和淋巴肉瘤)与HLA - DR和Leu - 1抗体均有反应。相反,正常B淋巴细胞和B细胞起源的淋巴样细胞系不表达Leu - 1抗体识别的表面抗原。